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ABSTRACT
OBJECTIVE
To assess the efficacy of three months of antibiotic 
treatment compared with placebo in patients with 
chronic low back pain, previous disc herniation, and 
vertebral endplate changes (Modic changes).
DESIGN
Double blind, parallel group, placebo controlled, 
multicentre trial.
SETTING
Hospital outpatient clinics at six hospitals in Norway.
PARTICIPANTS
180 patients with chronic low back pain, previous disc 
herniation, and type 1 (n=118) or type 2 (n=62) Modic 
changes enrolled from June 2015 to September 2017.
INTERVENTIONS
Patients were randomised to three months of oral 
treatment with either 750 mg amoxicillin or placebo 
three times daily. The allocation sequence was 
concealed by using a computer generated number on 
the prescription.
MAIN OUTCOME MEASURES
The primary outcome was the Roland-Morris Disability 
Questionnaire (RMDQ) score (range 0-24) at one year 
follow-up in the intention to treat population. The 
minimal clinically important between group difference 
in mean RMDQ score was predefined as 4.
RESULTS
In the primary analysis of the total cohort at one year, 
the difference in the mean RMDQ score between the 
amoxicillin group and the placebo group was −1.6 
(95% confidence interval −3.1 to 0.0, P=0.04). In the 
secondary analysis, the difference in the mean RMDQ 
score between the groups was −2.3 (−4.2 to−0.4, 
P=0.02) for patients with type 1 Modic changes and 
−0.1 (−2.7 to 2.6, P=0.95) for patients with type 2 
Modic changes. Fifty patients (56%) in the amoxicillin 
group experienced at least one drug related adverse 
event compared with 31 (34%) in the placebo group.
CONCLUSIONS
In this study on patients with chronic low back pain 
and Modic changes at the level of a previous disc 
herniation, three months of treatment with amoxicillin 
did not provide a clinically important benefit compared 
with placebo. Secondary analyses and sensitivity 
analyses supported this finding. Therefore, our results 
do not support the use of antibiotic treatment for 




The current management of low back pain offers low 
to moderate improvement in pain and disability.1 
Researchers therefore attempt to identify subgroups 
of patients who would benefit from specific treatment. 
A suggested subgroup of patients with chronic low 
back pain have signal changes in the vertebral bone 
marrow that extends from the endplate (Modic 
changes) on magnetic resonance imaging.2 Modic 
changes are classified into type 1 (oedema type), 
type 2 (fatty type), and type 3 (sclerotic type, less 
common).3 The pathogenesis of Modic changes is 
unclear. One hypothesis is that Modic changes and 
low back pain are caused by low grade bacterial 
discitis caused by Cutibacterium acnes (formerly 
known as Propionibacterium acnes), an aerotolerant 
Gram positive anaerobe bacteria and a common skin 
commensal.4 The proposed port of entry into the disc 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
A systematic review from 2015 found only one randomised controlled trial that 
assessed the efficacy of antibiotic treatment in patients with chronic low back 
pain and Modic changes
This former trial reported a substantial effect of three months of antibiotic 
treatment over placebo (difference between groups of 8.3 points on the Roland-
Morris Disability Questionnaire (RMDQ) at one year follow-up)
WHAT THIS STUDY ADDS
This study did not replicate the findings of the previous randomised controlled 
trial
Three months of treatment with amoxicillin did not provide a clinically important 
benefit compared with placebo in patients with chronic low back and Modic 
changes
The largest observed mean difference between the treatment groups (2.3 points 
on the RMDQ for patients with type 1 Modic changes) was substantially smaller 
and below the predefined clinically important between group difference
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is through the bloodstream, which is made possible 
during vascularisation related to inflammation caused 
by a disc herniation.5 Animal models show that C acnes 
could grow in degenerated discs and cause Modic 
changes.6 7 However, several microbiological studies of 
disc biopsies have conflicting results.4
A systematic review found only one randomised 
trial that assessed the efficacy of antibiotic treatment 
in patients with low back pain.4 The trial reported 
a substantial effect of three months of antibiotic 
treatment compared with placebo (between group 
difference of 8.3 points on the Roland-Morris 
Disability Questionnaire (RMDQ) at one year follow-
up) in patients with chronic low back pain, prior 
disc herniation, and type 1 Modic changes.8 The trial 
conclusion has been questioned based on almost no 
improvement in the control group,9 no evaluation of 
blinding efficacy, and a high proportion of participants 
with previous disc surgery and thus a potential risk of 
bacterial contamination.10 Current guidelines do not 
include recommendations (for or against) antibiotic 
treatment in patients with persistent low back pain 
and Modic changes.11 About 40-50% of patients with 
non-specific low back pain have Modic changes, and 
antibiotic treatment in subgroups of this large patient 
population could increase antibiotic resistance.12-14
We aimed to replicate the findings in the former 
randomised trial. This trial evaluated the efficacy and 
harm of three months of oral treatment with amoxicillin 
at one year follow-up in patients with chronic low back 
pain and type 1 or 2 Modic changes at the level of a 
previous lumbar disc herniation.
Methods
Study design
This was a multicentre, randomised, double blind, 
placebo controlled, parallel group trial with a treatment 
phase (three months) and a follow-up phase (nine 
months). The trial was performed in accordance with the 
Helsinki Declaration and the International Conference 
on Harmonisation of Good Clinical Practice, reported 
according to the CONSORT guidelines,15 and was 
registered at ClinicalTrials.gov in December 2014 under 
the identifier: NCT02323412. The Regional Committees 
for Medical Research Ethics South East Norway 
(2014/158/REK sør-øst) and the Norwegian Medicines 
Agency (SLV; reference No 14/01368-11; EudraCT No 
2013-004505-14) approved the trial before it started. 
The Clinical Trial Unit at Oslo University Hospital 
monitored the trial. All participants gave written 
informed consent. Methods were unchanged after trial 
commencement. Funding was granted by governmental 
organisations (Helse Sør-Øst and Helse Vest), which had 
no part in the planning, performing, or reporting of the 
trial. The trial protocol is available at ClinicalTrials.gov.
Participants
We recruited patients from outpatient clinics at six 
hospitals in Norway from June 2015 to September 2017. 
Inclusion criteria were age 18-65 years; low back pain 
for more than six months with intensity of at least 5 on 
a 0-10 numerical rating scale (mean of current, worst 
within the preceding two weeks, and usual/mean within 
the preceding two weeks); lumbar disc herniation on 
magnetic resonance imaging in the preceding two years; 
and type 1 or type 2 Modic changes (with height ≥10% of 
vertebral height and diameter >5 mm) at the herniated 
disc level. In contrast to the trial we were reassessing, 
we chose to include patients with type 2 Modic changes 
because differentiating between type 1 and type 2 Modic 
changes is of uncertain relevance and might depend 
on the magnetic field strength of the MRI scanner 
used.16 17 We excluded patients who had surgery for disc 
herniation in the past year or antibiotic treatment in the 
past month. Figure S1 in the supplementary appendix 
contains all eligibility criteria.18
Randomisation, masking, and procedures
Patients were randomised at a median of 13 days after 
inclusion into either three months of oral treatment 
with amoxicillin 750 mg three times daily or placebo 
(maize starch). The tablets were encapsulated (Kragerø 
Tablettproduksjon AS), with identical capsules, 
containers, and labels for both treatment groups. A third 
party statistician created randomisation lists by using 
Stata 13 (StataCorp, College Station, TX, USA). Lists were 
stratified by Modic change type (1 or 2) and previous disc 
herniation surgery or not, with a 1:1:1:1 allocation and 
random block sizes of four and six; this approach ensured 
that a similar number of patients received antibiotics or 
placebo within each stratum. The allocation sequence 
was concealed. Care providers gave each patient a 
prescription with a computer generated allocation 
number to be used at the dedicated hospital pharmacies. 
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Amoxicillin did not provide a clinically important benefit compared 
with placebo. Results do not support the use of antibiotic treatment 
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All care providers, research staff, statisticians, and 
patients were unaware of the assignment group during 
the data collection. Care providers, research staff, and 
statisticians were also blinded during primary and 
secondary analyses and first draft of this manuscript. 
We recommended that participants should not start 
additional treatments for back pain, but they were 
allowed to continue ongoing treatment. We encouraged 
participants not to use non-steroidal anti-inflammatory 
drugs during the intervention period.
To confirm Modic changes seen on a clinical MRI scan 
available at screening, baseline MRI was performed at 
a median of 22 days (interquartile range 15-30) before 
treatment initiation by using identical 1.5 T protocols 
at each study centre. We allocated patients with 
primary (most extensive) or secondary type 1 Modic 
changes (hypointense on T1 images, hyperintense 
on T2 images) to the type 1 Modic change group. 
Patients with type 2 Modic changes (hyperintense on 
T1, isointense or hyperintense on T2) but not type 1 
Modic changes were included in the type 2 Modic 
change group. We rated borderline type 1 versus type 
2 Modic changes (near isointense on T1) as type 2. 
Two experienced radiologists independently evaluated 
Modic changes on the baseline MRI, disc herniation on 
MRI scans from the previous two years, and eligibility 
for the trial in the type 1 versus type 2 Modic change 
group versus being ineligible (κ=0.62). The radiologists 
discussed and solved all disagreements on eligibility.
Outcomes and data collection
The primary outcome was the score on the validated 
Norwegian version of the RMDQ at one year follow-
up. RMDQ scores range from 0 to 24. Higher scores 
indicate more severe pain and disability. Secondary 
outcomes included pain related disability (Oswestry 
Disability Index 2.0), low back pain intensity (0-10 
numerical rating scale), and health related quality of 
life (EuroQol’s health related quality of life (EQ5D-5L), 
version 2.0). Trial measurements were unchanged 
after trial commencement and were reported at several 
time points (table S1, supplementary appendix) 
by using a web based data capture system (Viedoc) 
or, in a few cases, using a paper version. Trial care 
providers (physicians or physiotherapists) performed 
active surveillance of side effects and adverse events 
(clinical and biochemical) from baseline to one year 
using Common Terminology of Clinical Adverse Events 
version 4.0 in accordance with Medical Dictionary for 
Regulatory Activities (medDRA) coding.19 Adverse events 
were monitored and cross checked against clinical 
patient notes, and we report all of them in this study. We 
monitored compliance by using weekly patient reported 
questionnaires and by counting the returned study drug 
capsules at the end of treatment visit (table S1)
Statistical analysis
We specified all main statistical analyses in a statistical 
analysis plan in advance of database locking.20 
Retrospective analyses not described in the statistical 
analysis plan are highlighted in the paper and the tables.
In the primary analysis we compared mean RMDQ 
scores between the two treatment groups in the whole 
intention to treat population at one year by using analysis 
of covariance and adjusting for baseline RMDQ score 
and the stratification variables. Missing RMDQ values 
were imputed with a multiple imputation model.20 In the 
secondary analyses, we repeated this comparison in each 
Modic change type group. We also performed analyses 
of key supportive objectives (secondary outcomes: 
Oswestry Disability Index, low back pain intensity, and 
EQ5D-5L); per protocol analysis and other sensitivity 
analyses; responder analyses (>30%, >50%, and >75% 
improvement from baseline, excluding patients with 
>30% missing RMDQ items); and linear mixed effects 
models as described in the statistical analysis plan.20 
An exploratory objective was to report the incidence 
of adverse events that occurred from randomisation 
to one year follow-up. Adverse events were presented 
descriptively for the safety population according to 
intervention group, without statistical testing.
We predefined a clinically important between group 
difference in mean RMDQ score as 4. We did not consider 
smaller differences to be clinically relevant in this trial 
(although another study regarded a difference of 2.5 to 
be relevant21) because we were reassessing the potential 
curative effect of antibiotic treatment; additionally, 
a much higher difference (8.3) was reported in the 
former trial.8 In comparison, a change of 2-3 RMDQ 
points in individual patients over time could represent 
measurement error,22 and the minimal detectable change 
of the RMDQ was 4 in a Norwegian study of chronic low 
back pain patients.23 In each Modic change type group, 
we needed 66 analysed patients to detect (β=0.1, α=0.05) 
a difference of 4 (standard deviation 5) in mean RMDQ 
score between the two treatment groups. In the total 
sample, 132 analysed patients allowed detection (β=0.1, 
α=0.05) of a difference of 2.8 (standard deviation 5) in 
mean RMDQ score. We added 20% to allow for dropouts 
and planned to include 80 participants in each group.
When half of the study participants had completed 
their one year assessment, an independent statistician 
blinded to treatment groups performed a prespecified 
interim analysis to ensure that continuation of the 
study was ethical. If mean RMDQ score differed by 
more than 7 points between the two treatment groups, 
an independent data monitoring committee could 
recommend the study should be stopped. No results 
from the interim analysis were communicated to the trial 
staff. We did not adjust the significance level due to the 
interim analysis because the trial did not have a group 
sequential design and only had one primary analysis.
We calculated the Bang blinding index in each treatment 
group based on patients’ reports at one year follow-up 
about which treatment they thought they had received 
(antibiotics, placebo, or unsure). The Bang blinding index 
ranges from −1 (all patients report incorrect treatment) 
to 1 (all patients report correct treatment); 0 indicates 
random reporting of treatment group.24
A senior statistician independently carried out primary, 
secondary, and key supportive objectives analyses by 
using software package R (version 3.4.4); a PhD student 
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also performed these analyses with software package 
Stata (version 15). Both were blinded to treatment group.
Patient and public involvement
A patient representative was a member of the 
scientific board of the study, which made all the 
major decisions from planning and design of the 
study, to the dissemination of the study results. The 
patient representative assessed the burden of the 
study medication and the time and effort required to 
participate in the trial, and took part in writing this 
manuscript. We plan to disseminate the results to study 
Assessed for eligibility
Excluded
Not meeting inclusion/exclusion criteria
  No disc herniation within last two years 
  Pain intensity score too low
  Comorbidity (other low back pain
    diagnosis or previous surgery other
    than for disc herniation)
  Other inclusion/exclusion criteria not




Allocated to placebo and started study drug
Reported baseline RMDQ90
Allocated to amoxicillin and started study drug
Reported baseline RMDQ88










Stopped study drug due to an adverse event
  related to protocol deviation*
Stopped study drug due to adverse events
  related to study drug†
Was non-complier and later stopped study






Patients evaluated at 1 year follow-up
Reported RMDQ at 1 year
Completed study without major protocol
  deviations (per protocol population)
End of study before 3 months (see box
  above)
Treatment non-completion†
Operation for disc herniation
Incorrect enrolment¶









Patients evaluated at 1 year follow-up
Reported RMDQ at 1 year
Completed study without major protocol
  deviations (per protocol population)
End of study before 3 months (see box
  above)
Treatment non-completion
Diagnosed as having spondyloarthritis
Given both amoxicillin and placebo**
Incorrect enrolment††
























Stopped study drug due to an adverse event
  related to protocol deviation*






Fig 1 | Flowchart showing trial group assignments, loss to follow-up, treatment completion, and protocol deviations. 
RMDQ=Roland-Morris Disability Questionnaire. *One patient in amoxicillin group and one patient in placebo group 
became pregnant (protocol deviation because all patients were instructed to use contraception), not included in per 
protocol population. †Three patients in amoxicillin group stopped study drug because of adverse events and were 
included in per protocol population. ‡One patient in amoxicillin group stopped study drug because of adverse events 
but was not included in per protocol population owing to poor compliance before stopping study drug. §Two patients 
in placebo group discontinued because they started three month treatment with amoxicillin plus clavulanic acid. 
¶Treated with apocillin seven days before randomisation. **Because of a mistake at pharmacy, patient was given a 
mix of bottles containing amoxicillin and placebo. ††Treated with cephalexin seven days before randomisation.
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participants and the patient organisation (Norwegian 
Back Pain Association) before publication.
Results
Patients
Figure 1 summarises the trial group assignments, 
loss to follow-up, treatment completion, and protocol 
deviations. Of the 582 patients assessed for eligibility, 
180 underwent randomisation; 118 with type 1 Modic 
changes and 62 with type 2 Modic changes. Because 
inclusion of patients with type 1 Modic changes 
was faster, enrolment was closed before the goal for 
recruiting patients with type 2 Modic changes had been 
met (in September 2017). We prospectively presumed at 
the time of enrolment closure that a power of 88% (using 
the same specifications as given above for 62 patients) 
for the type 2 Modic change group was sufficient.
Table 1 shows baseline characteristics of participants 
and table 2 presents baseline values of the outcomes. 
The placebo group had a higher percentage of 
participants with jobs that required physical workload. 
We did not consider any other differences between the 
treatment groups to be relevant. In total, 38 patients 
(21%) had previous surgery for disc herniation. All 
180 randomised patients started on the study drug 
and were included in the intention to treat analysis. Of 
these, 155 patients were included in the per protocol 
analysis.
Outcomes
At one year, the mean RMDQ score had reduced since 
baseline in both treatment groups (−3.7 points in 
the amoxicillin group and −2.1 points in the placebo 
group) (table 2 and fig 2). The adjusted mean difference 
in RMDQ score between the amoxicillin group and 
the placebo group at one year was −1.6 points (95% 
confidence interval −3.1 to 0.0, P=0.04) (table 2). The 
adjusted between group difference of the mean RMDQ 
score was −2.3 (95% confidence interval −4.2 to 
−0.4, P=0.02) for patients with type 1 Modic changes 
and −0.1 (−2.7 to 2.6, P=0.95) for patients with type 
2 Modic changes. Table 2 and table 3 summarise 
analyses of the secondary outcomes. The responder 
analyses (table S2) and sensitivity analyses (table S5) 
are summarised in the supplementary appendix.
Adverse events
In the amoxicillin group, 50 patients (56%) had 
at least one drug related adverse event (possibly/
probably/definitely related to study drug) compared 
with 31 patients (34%) in the placebo group. One or 
more serious adverse events occurred in six patients 
(7%) in the amoxicillin group and two patients (2%) 
in the placebo group; none was related to the study 
drug (table 4). In the amoxicillin group, 11 patients 
(12%) discontinued or paused the study drug because 
of adverse events compared with two patients (2%) in 
the placebo group. No deaths occurred during the trial.
Blinding
A total of 167 patients responded to the blinding 
question at one year. The Bang blinding index was 
−0.16 (95% confidence interval −0.31 to −0.01, 
P=0.96) in the amoxicillin group and 0.52 (0.40 to 




In this study on patients with chronic low back pain 
and Modic changes at the level of a previous disc 
herniation, three months of treatment with amoxicillin 
did not provide a clinically important benefit compared 
with placebo. Secondary analyses and sensitivity 
analyses supported this finding.
The analyses of secondary outcomes also 
found considerably smaller differences than the 
recommended thresholds for a clinically important 
change within groups (ranges of recommended 
thresholds: Oswestry Disability Index 13-20; low back 
pain intensity numerical rating scale 2-3; EQ5D-5L 
0.11-0.30).28-30 Fifty patients (56%) in the amoxicillin 
Table 1 | Baseline characteristics of participants in treatment groups. Values are No/total 
No (%) unless stated otherwise
Amoxicillin Placebo
Age (mean (SD)) 44.7 (9.0), n=89 45.2 (9.0), n=91
Women 53/89 (60) 52/91 (57)
Body mass index (mean (SD)) 26.1 (4.1), n=89 25.9 (4.0), n=90
Smoking, yes 25/89 (28) 21/89 (24)
Educational level:
 Primary school (9 years) 10/88 (11) 9/89 (10)
 High school (12 years) 36/88 (41) 42/89 (47)
 College or university (<4 years) 27/88 (31) 18/89 (20)
 University (≥4 years) 15/88 (17) 20/89 (22)
Comorbidity*: 
 Score 1 (back pain only) 62/89 (70) 60/91 (66)
 Score 2 21/89 (24) 27/91 (30)
 Score >2 6/89 (7) 4/91 (4)
Previous disc surgery 18/89 (20) 20/91 (22)
Emotional distress (HSCL-25≥1.75)† 24/88 (27) 23/91 (25)
FABQ physical activity (0-24)‡ (mean (SD)) 11.2 (5.9), n=89 12.6 (5.8), n=90
FABQ work (0-42)‡ (mean (SD)) 17.0 (11.7), n=87 18.9 (12.0), n=89
Duration of back pain (years) (median (IQR)) 3.0 (1.5-5.6), n=89 3.4 (1.7-7), n=90
Physical workload: 
 Mostly sitting 37/77 (48) 26/74 (35)
 Job requires a lot of walking 20/77 (26) 20/74 (27)
 Job requires a lot of walking and lifting 17/77 (22) 24/74 (32)
 Job requires physically heavy work 3/77 (4) 4/74 (5)
Employment status:
 Working full time 46/89 (52) 43/91 (47)
 Partial sick leave 14/89 (16) 20/91 (22)
 Complete sick leave 22/89 (25) 16/91 (18)
 Disability pension 3/89 (3) 7/91 (8)
 Unemployed 2/89 (2) 3/91 (3)
 Student/other/unknown 2/89 (2) 2/91 (2)
Modic type 1 group 58/89 (65) 60/91 (66)
Level of Modic change and previous disc herniation: 
 L1/L2 0/89 0/91
 L2/L3 2/89 (2) 2/91 (2)
 L3/L4 7/89 (8) 5/91 (5)
 L4/L5 48/89 (54) 29/91 (32)
 L5/S1 58/89 (65) 74/91 (81)
SD=standard deviation; IQR=interquartile range. 
*Functional Comorbidity Index25; score increased by 1 for each of 18 diagnoses associated with decreased 
physical function.
†Emotional distress (Hopkins Symptom Checklist 25); values ≥1.75 associated with psychiatric diagnosis.26
‡Fear avoidance beliefs questionnaire27; higher values indicate more fear avoidance beliefs.
copyright.
 on 28 D
ecem
ber 2019 at H












J: first published as 10.1136/bm






6 doi: 10.1136/bmj.l5654 | BMJ 2019;367:l5654 | the bmj
group compared with 31 (34%) in the placebo group 
experienced at least one drug related adverse event.
Comparison with the previous study
Our results are not consistent with the findings of the 
trial we were reassessing, which showed a substantial 
effect (between group difference of 8.3 points on the 
RMDQ score) in patients who received a combination 
treatment of amoxicillin and clavulanic acid for three 
months.8 In our study, amoxicillin was used without 
clavulanic acid. Because there is little or no resistance 
to penicillin among C acnes in vitro,31 and it is known 
that penetration of discs by clavulanic acid is poor,32 33 
we consider the difference in treatment regimens to 
be an unlikely explanation for the inconsistent trial 
results. The trial we were reassessing reported a non-
significant difference in effect between amoxicillin plus 
clavulanic acid 500/125 mg and 1000/250 mg three 
times daily.8 However, the pharmacodynamic property 
that predicts treatment success with amoxicillin is time 
above the minimum inhibitory concentration. Further 
increases in amoxicillin concentration do not increase 
bactericidal activity, which suggests there should be 
a minimal dose–response relation. Thus, we consider 
the dosage of amoxicillin used in the present trial, 750 
mg three times daily, to be sufficient.
The former trial included a higher percentage 
of patients with previous disc surgery (52% in the 
antibiotic group) compared with our study (20% in 
the antibiotic group) and had relatively fewer patients 
at follow-up in the antibiotic treatment group (86% 
v 96% in our trial). We cannot rule out that this 
might have influenced the differences in results. The 
improvement in RMDQ score from baseline to one 
year follow-up in the placebo group was smaller in 
the previous trial (from 15.0 to 14.0 v 12.8 to 10.7 in 
our trial). It is difficult to evaluate whether this could 
have been owing to poor blinding in the previous study 
because data on blinding efficacy were lacking.
Clinical relevance
Our trial’s predefined minimal clinically important 
between group difference of 4 points on the RMDQ 
is larger than that used in some other randomised 
trials of patients with low back pain. However, it 
can be considered conservative given the results 
of the trial we were reassessing and the proposed 
rationale for the treatment that an infection leads to 
Modic changes and low back pain. If the symptoms 
were mainly because of an infection with C acnes, 
we would expect a large symptom improvement 
with effective antibiotic treatment. Perhaps also 
Table 2 | Primary and secondary outcomes for treatment groups and treatment comparisons (adjusted mean difference) 
for all time periods
Outcome
Amoxicillin Placebo ANCOVA Linear mixed effects‡
No* Mean (SD) No Mean (SD) No† Mean (95% CI) P value Mean (95% CI) P value
RMDQ:
 Baseline 88 12.7 (4.7) 90 12.8 (3.7) — — — — —
 3 months 85 10.3 (5.8) 87 12.4 (4.4) 180 −1.9 (−3.2 to −0.7) 0.003 −1.9 (−3.3 to −0.5) 0.006
 6 months 83 9.9 (5.9) 78 11.7 (5.2) 179§ −1.5 (−2.9 to 0.0)¶ 0.047 −1.6 (−3.2 to −0.1) 0.04
 9 months 77 9.7 (6.4) 79 11.1 (5.4) 179§ −1.6 (−3.1 to 0.0)¶ 0.049 −1.7 (−3.3 to −0.1) 0.04
 12 months 85 9.0 (6.2) 84 10.7 (5.6) 180 −1.6 (−3.1 to 0.0) 0.04 −1.7 (−3.3 to −0.1) 0.04
ODI:
 Baseline 88 31.9 (11.4) 89 31.8 (10.3) — — — — —
 3 months 86 26.6 (14.7) 85 30.4 (10.7) 179§ −3.8 (−6.7 to −0.9)** 0.01 −4.1 (−7.0 to −1.2) 0.006
 12 months 85 24.4 (15.0) 84 28.9 (14.0) 179§ −4.8 (−8.3 to −1.4)** 0.007 −5.1 (−8.5 to 1.6) 0.004
Back pain intensity††:
 Baseline 88 6.4 (1.2) 90 6.3 (1.5) — — — — —
 3 months 85 5.2 (2.3) 85 5.4 (1.9) 179§ −0.3 (−0.8 to 0.3)** 0.33 −0.4 (−0.8 to 0.1) 0.13
 6 months 83 5.1 (2.2) 77 5.5 (2.2) 178§ −0.5 (−1.1 to 0.1)¶** 0.11 −0.5 (−1.0 to 0.0) 0.03
 9 months 78 5.2 (2.4) 77 5.0 (2.3) 178§ 0.0 (−0.7 to 0.6)¶** 0.97 0.0 (−0.5 to 0.5) 0.88
 12 months 85 4.7 (2.3) 84 5.2 (2.3) 179§ −0.6 (−1.3 to 0.0)** 0.06 −0.7 (−1.2 to −0.2) 0.005
EQ5D-5L:
 Baseline 89 0.55 (0.19) 91 0.54 (0.18) — — — — —
 3 months 85 0.60 (0.22) 83 0.54 (0.21) 180 0.06 (0.00 to 0.11)** 0.04 0.06 (0.00 to 0.11) 0.05
 12 months 84 0.65 (0.22) 83 0.58 (0.22) 180 0.07 (0.02 to 0.12)** 0.01 0.07 (0.01 to 0.13) 0.015
Leg pain intensity (0-10):
 Baseline 89 3.2 (2.6) 90 3.2 (2.6) — — — — —
 3 months 85 3.1 (2.8) 84 3.4 (2.6) 168 −0.3 (−0.9 to 0.4)¶** 0.42 — —
 12 months 85 2.8 (2.7) 82 3.5 (2.8) 166 −0.8 (−1.4 to −0.1)¶** 0.03 — —
ANCOVA=analysis of covariance; EQ5D-5L=EuroQol’s health related quality of life (score from −0.59 to 1; higher scores indicate better quality of 
life); ODI=Oswestry Disability Index (score from 0 to 100; higher scores indicate more severe pain and disability); RMDQ=Roland-Morris Disability 
Questionnaire (score from 0 to 24; higher scores indicate more severe pain and disability).
*Number of answered questionnaires of outcome.
†Number of cases included in the analyses after multiple imputations.
‡Interaction between time and treatment at 12 months with simple contrasts.
§Some patients excluded from analysis because the imputation model did not manage to impute all missing variables.
¶Retrospective analyses not described in the registry.
**Estimates smaller than recommended thresholds for clinical important change within groups (ODI 13-20; low back pain intensity numerical rating scale 
2-3; leg pain intensity numerical rating scale 2-3.5; EQ5D-5L 0.11-0.30).
††Linear mixed effects model includes all time points (week 0-13).
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the nature of the intervention, with its associated 
risk of complications and contribution to antibiotic 
resistance, suggest we should demand a larger 
effect size than for many other suggested treatment 
options for low back pain. Patients require a 30% 
extra improvement when taking non-steroidal anti-
inflammatory drugs compared with no intervention,34 
which equates approximately to our predefined 
level of difference. We observed a small, statistically 
significant treatment effect for the primary outcome 
and two secondary outcomes (Oswestry Disability 
Index and EQ5D-5L), and among patients with type 1 
Modic changes, all in favour of the amoxicillin group. 
However, the study was overpowered for all these 
analyses. The statistically significant effect sizes are 
small and most likely not clinically relevant for the 
whole study population.
In addition, patients’ expectations of treatment 
effect might partly explain the effect (table S5, 
supplementary appendix). We cannot exclude a 
clinically relevant effect for some patients with type 1 
Modic changes because the 95% confidence interval 
for RMDQ (−4.2 to −0.4) only just included the 
difference of 4 that the study was designed to detect. 
Nevertheless, the true difference is probably less than 
4. The results for the secondary outcomes in the type 
1 Modic change group were similar and indicated no 
clinically relevant between group differences.
Limitations and generalisability
This study has some limitations. The main limitation 
was the initiation of antibiotic treatment without first 
documenting infection in tissue samples taken from 
individual patients. Such microbiological investigations 
were not performed owing to risk of complications and 
suspected low diagnostic yield from samples with low 
grade infection obtained with needle biopsies.35 A 
second, related limitation is the heterogeneity of the 
treated sample. We cannot exclude the possibility of 
treatment effect in subgroups. Thirdly, a Bang blinding 
index of 0.52 (95% confidence interval 0.40 to 0.64) 
in the placebo group indicates there was some degree 
of unblinding in this group, which potentially reduced 
the placebo effect in the placebo group, and caused a 
falsely high between group treatment effect. However, 
blinding seemed to be maintained in the amoxicillin 
group, which reduced the impact of possible biases. 
The main determinants of reporting antibiotic 
treatment were improvement of symptoms and adverse 
events (table S4, supplementary appendix). Finally, 
we cannot rule out the possibility that some patients in 
the placebo group took amoxicillin without telling us, 
which could have influenced the difference in outcome 
between the treatment groups. To reduce this problem 
we meticulously registered all drugs. External monitors 
cross checked all registered drugs with patients’ notes.
The inclusion and exclusion criteria of this study, 
for example relating to herniation, pain score, age, 
and other diseases, could reduce its generalisability. 
Particularly, adverse events are more likely to occur 
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Fig 2 | Roland-Morris Disability Questionnaire score and low back pain intensity 
(numerical rating scale) from baseline to one year
Table 3 | Work, global perceived effect, patient satisfaction, and drug use. Values are No/
total No (%) unless stated otherwise
Outcome
Treatment group Treatment comparison,  
P value¶Amoxicillin Placebo
Working (including part time sick leave):
Baseline 60/89 (67) 63/91 (69) —
1 year 56/85 (63) 53/84 (58) 0.62
Global perceived effect at 1 year*:
Improved 24/85 (28) 18/84 (21) 0.39
No change 58/85 (68) 60/84 (71)
Worse 3/85 (4) 6/84 (7)
Patient satisfaction at 1 year:
Satisfied 35/85 (41) 28/84 (33) 0.52
Somewhat satisfied 8/85 (9) 9/84 (11)
Neither satisfied nor dissatisfied 34/85 (40) 35/84 (42)
Somewhat dissatisfied 5/85 (6) 4/84 (5)
Dissatisfied 3/85 (4) 8/84 (10)
Concomitant drug treatment use: 
Analgesics, any: 
 Baseline† 62/89 (70) 61/91 (67) —
 1 year 61/89 (69) 67/91 (74) 0.45
NSAIDs: 
 Baseline‡ 38/89 (43) 36/91 (40) —
 1 year 39/89 (44) 40/91 (44) 0.99
Opioids:
 Baseline§ 28/89 (31) 27/91 (30) —
 1 year 28/89 (31) 35/91 (38) 0.33
NSAID=non-steroidal anti-inflammatory drug.
*Seven point Likert scale recoded to three categories (improved=completely recovered, much better; no 
change=somewhat better, no change, somewhat worse; worse=much worse, worse than ever).
†Five patients in the amoxicillin group and four patients in the placebo group reported taking analgesics for 
reasons other than low back pain only.
‡Two patients in the amoxicillin group reported taking NSAIDs for reasons other than low back pain only.
§No patient took strong opioids. One patient in the placebo group reported taking opioids for reasons other than 
low back pain only.
¶Comparison of data only at one year follow-up.
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mechanism that could make a treatment effect of 
amoxicillin more likely in the excluded groups.
Balancing the trial findings
The proportion of patients with drug related adverse 
events in this study was higher than reported in the 
literature for long term treatment with penicillins,37 
and was also high in the placebo group (34%). 
Possible explanations for this finding are that common 
complaints in the general population mimic adverse 
events, the meticulous registration of adverse events 
in our trial, and some nocebo effects. Our findings that 
12% in the amoxicillin group versus 2% in the placebo 
group discontinued or paused the study drug because 
of adverse events, and that no patients experienced 
drug related serious adverse events, are consistent 
with previous studies.37
The responder analyses suggest that between five 
and 18 patients need to be treated for one to improve; 
numbers and statistical significance vary depending on 
cut-off values for definition of improvement. The nature 
of our intervention suggests that we should require high 
cut-off values. It is our opinion that the numbers do not 
justify three months of treatment with antibiotics when 
we consider the increase in adverse events and the 
context of increasing antibiotic resistance worldwide. 
In addition, differences between the treatment 
groups were not consistent across all patient reported 
outcomes, which further questions the relevance of the 
small between group difference in the primary analysis.
Conclusions and policy implications
In conclusion, we were not able to replicate the 
findings of the previous randomised trial. Our study 
did not show any clinically important effect of three 
months of oral antibiotic treatment in patients with 
chronic low back pain, Modic changes, and a former 
herniated disc. Our results do not support the use of 
antibiotic treatment for chronic low back pain and 
Modic changes.
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